Shopping Cart
- Remove All
Your shopping cart is currently empty
CNX-2006
Catalog No. T6008Cas No. 1375465-09-0
Alias CNX2006, CNX 2006
CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
CNX-2006
Catalog No. T6008Alias CNX2006, CNX 2006Cas No. 1375465-09-0
CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $34 | In Stock | |
| 2 mg | $48 | In Stock | |
| 5 mg | $76 | In Stock | |
| 10 mg | $128 | In Stock | |
| 25 mg | $235 | In Stock | |
| 50 mg | $425 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $92 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CNX-2006"
Gefitinib
Cited
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $50
Size
QTY
CitedErlotinib Cited
R1415, OSI-744, NSC 718781, CP358774
T0373183321-74-6
Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
- $40
Size
QTY
CitedOsimertinib Cited
Mereletinib, AZD-9291
T24901421373-65-0
Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
- $32
Size
QTY
CitedLapatinib Cited
GW572016, GSK572016
T0078231277-92-2
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
- $29
Size
QTY
CitedNeratinib Cited
HKI-272
T2325698387-09-6
Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.
- $30
Size
QTY
CitedGenistein Cited
NPI 031L
T1737446-72-0
Genistein (NPI 031L) is a naturally occurring soy isoflavone, a multi-targeted tyrosine kinase inhibitor. Genistein has antitumor, antioxidant, and anthelmintic properties, and also produces estrogen-like effects in the body.
- $38
Size
QTY
CitedErlotinib hydrochloride
OSI-744, NSC 718781, Erlotinib HCl, CP-358774
T0373L183319-69-9
Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
- $35
Size
QTY
Lidocaine Hydrochloride hydrate
T1144L6108-05-0
Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.
- $32
Size
QTY
Chalcone
β-phenylacrylophenone, phenyl styryl ketone, Cinnamophenone, benzylideneacetophenone, benzalacetophenone
T2S096194-41-7
Chalcone (Cinnamophenone) is an aromatic ketone that forms the central core for a variety of important biological compounds, which are known collectively as chalcones.
- $31
Size
QTY
Afatinib Dimaleate Cited
BIBW2992, BIBW 2992MA2, Afatinib (BIBW2992) Dimaleate, Afatinib
T1773850140-73-7
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
- $34
Size
QTY
CitedKhellin Cited
Visammin, Methafrone, Amicardine
T143182-02-0
Khellin (Methafrone) is a vasodilator that also has bronchodilatory action.
- $32
Size
QTY
CitedOsimertinib mesylate Cited
Mereletinib mesylate, AZD-9291 mesylate
T36341421373-66-1
Osimertinib mesylate (AZD-9291 mesylate) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib mesylate has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
- $45
Size
QTY
CitedSelect Batch
Purity:99.16%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR. |
| Targets&IC50 | EGFR (mutant):<20 nM |
| In vitro | CNX-2006 is a novel irreversible EGFR tyrosine kinase inhibitor, specifically inhibits activating mutations of EGFR as well as the T790M mutation while having very weak inhibition at wild-type EGFR. In in vitro modeling of acquired resistance, continuous CNX-2006 treatment on drug-sensitive EGFR mutant cells leads to resistance more slowly than erlotinib. Dose escalation with CNX-2006 leads to differential effects in different lines, but does not select for T790M-mediated resistance. [1]CNX-2006 resistent cells shows increased expression of EMT markers and MMP9.[2] |
| In vivo | CNX-2006 is effective in H1975 (EGFR L858R/T790M) xenograft model. [1] [2] |
| Kinase Assay | Growth inhibition assays: Human EGFR mutant lung adenocarcinoma cell lines are treated with drugs in standard growth inhibition assays. |
| Cell Research | Cells with endogenous or transiently transfected mutant EGFRs (293 cells) are treated with inhibitors for 6 hours and then corresponding lysates are extracted and analyzed by immunoblotting.(Only for Reference) |
| Animal Research | Animal Models: Nude miceFormulation: 5% DMSO:15% Solutol HS15 in PBSDosages: 25 mg/kgAdministration: i.p. |
| Alias | CNX2006, CNX 2006 |
| Molecular Weight | 545.53 |
| Formula | C26H27F4N7O2 |
| Cas No. | 1375465-09-0 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMF: soluble DMSO: 91 mg/mL (166.8 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CNX-2006 | purchase CNX-2006 | CNX-2006 cost | order CNX-2006 | CNX-2006 chemical structure | CNX-2006 in vivo | CNX-2006 in vitro | CNX-2006 formula | CNX-2006 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.